Valeant Pharmaceuticals International (VRX) is in the Pharma Industry

• Sort by
• View by Content Type

• Valeant Pharmaceuticals International Q3 2008 Earnings Call Transcript

  Question-and-Answer Session Operator (Operator instructions.) Our first question comes from Michael Tong of Wachovia; your line is open. Michael Tong - Wachovia Capital Hi, good morning. Just a more philosophical question if you could, Mike. I have heard a lot of companies talk about preserving...

  Earnings calls 2008-11-06

  Tags: Acquisition, Call Transcript, Wachovia Corp., Earnings, Brean Murray Co., Valeant Pharmaceuticals International, Mergers & Acquisitions, Corporate Law, Research & Development, Investment, Finance, Business Operations, Seeking Alpha

• Valeant Pharmaceuticals International Q2 2008 Earnings Call Transcript

  Question-and-Answer Session Operator Mr. Gregg Gilbert. Greg Gilbert – Merrill Lynch Thanks. Good morning. First, a few for Peter; Peter, did I hear you correctly that your best estimate for the tax bill on the $392 –? Peter Blott Sorry, Gregg. They cut out. Yes. I...

  Earnings calls 2008-08-11

  Tags: Valeant Pharmaceuticals International

• Monday Options Outlook: AMZN, MCD, EL, CRME, VRX, CCK, CNO

  Rebecca Engmann Darst co-authored this article. Amazon.com AMZN ?Citigroup?s forecast of better-than-expected sales of its e-book reader Kindle sent shares of Amazon.com on a 10% tear to $88.66 this morning. Option traders responded with a wave of giddy and fresh action in front-month options that are due to expire...

  External links 2008-08-11

  Tags: US Market, Amazon.com Inc., Crown Holdings Inc., Conseco Inc., Estee Lauder Cos. Inc., McDonald's Corp., Valeant Pharmaceuticals International

• Stocks At or Near 52-Week Highs

  Hickey and Walters Bespoke submit: Below we highlight stocks in the S&P 1500 that are closest to their 52-week highs.  As shown, Covance CVD is the closest, followed by WCN, ADPT, PRXL and HBHC.  Key names on the list include AMGN, GIS, BAX, HNZ, JNJ, and QCOM.  In...

  External links 2008-08-07

  Tags: US Market, Adaptec Inc., Amgen Inc., Baxter International Inc., Church & Dwight Co. Inc., Conmed Corp., Compuware Corp., CryoLife Inc., Covance Inc., First Financial Bankshares Inc., General Mills Inc., Gentiva Health Services, Haemonetics Corp., Hancock Holding Co., H.J. Heinz Co., Johnson & Johnson, National Presto Industries Inc., Parametric Technology Corp., PAREXEL International Corp., Qualcomm Inc., QLogic Corp., Symantec Corp., Tetra Tech Inc., Varian Medical Systems Inc., Valeant Pharmaceuticals International, Waste Connections Inc.

• Valeant Pharmaceuticals International Q1 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator Instructions Our first question comes from Michael Tong from Wachovia Capital. Your line is open sir. Michael Tong - Wachovia Capital Hi. Good morning. Just one quick question. I was wondering whether I can get some idea as to how much of Efudex use is in...

  Earnings calls 2008-05-13

  Tags: Valeant Pharmaceuticals International

• Valeant Pharmaceuticals Announces New CEO and Chairman

  -- J. Michael Pearson Appointed CEO and Chairman -- -- Timothy C. Tyson Resigns as CEO and Director -- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has appointed J. Michael Pearson to the position of Chief Executive Officer of the Company, effective February...

  Research articles 2008-02-04

  Tags: board, CEO, McKinsey & Co., Readers, Valeant Pharmaceuticals International

• Valeant Pharmaceuticals Developing Intranasal Diazepam for the At-Home Treatment of Emergency Seizures

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it is developing an intranasal form of delivery for diazepam for the treatment of seizure emergencies in children and adults, in conjunction with researchers from the University of Minnesota. Valeant currently markets Diastat[R] AcuDial[TM] diazepam rectal gel -- the...

  Research articles 2007-01-25

  Tags: FDA, Government, patient, University of Minnesota, Valeant Pharmaceuticals International

• The Orange County Register, Calif., Business Briefs Column.

  The Orange County Register, Calif. Knight Ridder/Tribune Business News Feb. 13--FTC ENDS PROBE INTO PATENT OF ALLERGAN'S ACULAR: Irvine-based Allergan Inc., the maker of Botox anti-wrinkle treatments, said the U.S. Federal Trade Commission has closed its investigation into whether the company...

  Research articles 2004-02-13

  Tags: Allergan Inc., FINANCE, FTC, Orange PCS, Raining Data Corp., Valeant Pharmaceuticals International

Additional Resources

• Valeant Pharmaceuticals Acquires DermaTech

  -Purchase Expands Valeant's Dermatology Business in Australia- ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has acquired DermaTech Pty Ltd, an Australian specialty pharmaceutical company focused on dermatology products marketed throughout Australia and overseas, for approximately AU$19 million, with customary adjustments for net asset...

  Articles 2008-11-14

• Valeant Pharmaceuticals to Present at Lazard Capital Markets 5th Annual Healthcare Conference

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the Lazard Capital Markets 5th Annual Healthcare Conference on Wednesday, November 19, 2008 at 11:00 a.m. EST. The conference will be held at The St. Regis, New York,...

  Articles 2008-11-12

• Valeant Pharmaceuticals to Present at 2008 Credit Suisse Phoenix Health Care Conference

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE: VRX) today announced members of its senior management team will make a presentation at the 2008 Credit Suisse Phoenix Health Care Conference on Friday, November 14, 2008 at 9:30 a.m. MST. The conference will be held at the Arizona Biltmore Resort in...

  Articles 2008-11-07

• Valeant Pharmaceuticals Reports Third Quarter Financial Results

  * New $200 Million Securities Repurchase Program Approved by Board ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced third quarter financial results for 2008. Total revenue was $168.4 million in the third quarter of 2008 as compared to $164.3 million in the third quarter...

  Articles 2008-11-06

• Valeant Pharmaceuticals to Announce 2008 Third Quarter Results on November 6, 2008

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it will host a conference call on Thursday, November 6, 2008 at 10:00 a.m. EST (7:00 a.m. PST) to discuss results for the 2008 third quarter. The dial-in number to participate on this call is (877) 295-5743,...

  Articles 2008-10-22

• Valeant Pharmaceuticals and GlaxoSmithKline Complete Worldwide Collaboration Agreement for Retigabine

  Valeant Receives $125 Million Upfront ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has closed on its exclusive worldwide collaboration agreement with GlaxoSmithKline GSK for the investigational drug retigabine, a first-in-class neuronal potassium channel opener for the treatment of adult epilepsy patients with refractory...

  Articles 2008-10-17

• Valeant Pharmaceuticals Completes Acquisition of Coria Laboratories, Ltd

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has completed its acquisition of Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. Under the terms of the agreement, Valeant purchased all of the outstanding shares of Coria from parent...

  Articles 2008-10-16

• Valeant Pharmaceuticals Signs Agreement to Acquire Coria Laboratories, Ltd

  Purchase Expands Valeant's U.S. Dermatology Business ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) today announced that it has signed a definitive agreement to acquire Coria Laboratories, Ltd., a privately-held specialty pharmaceutical company focused on dermatology products in the United States. This transaction significantly expands Valeant's business in...

  Articles 2008-09-17

• DFB Sells Coria Labs to Valeant Pharmaceuticals

  FORT WORTH, Texas, Sept. 17 /PRNewswire/ -- H. Paul Dorman, Chairman and Chief Executive Officer of Fort Worth-based DFB Pharmaceuticals, Inc., today announced that DFB has signed a definitive agreement to sell its dermatology division Coria Laboratories, Ltd. to Valeant Pharmaceuticals International . Under the terms of...

  Articles 2008-09-17

• Valeant Announces Presentation of Retigabine Data at the 8th European Congress on Epileptology

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that clinical data for retigabine from the Phase III RESTORE program will be presented at the 8th European Congress on Epileptology, which will be held at the Berlin Internationales Congress Centrum ICC in Berlin, Germany, September 21-24, 2008. ...

  Articles 2008-09-15

• Swedish pharmaceuticals company Meda AB complete acquisition of European operations of Valeant Pharmaceuticals

  NORDIC BUSINESS REPORT-12 September 2008-Swedish pharmaceuticals company Meda AB complete acquisition of European operations of Valeant PharmaceuticalsC1994-2008 M2 COMMUNICATIONS LTD http://www.m2.com Swedish speciality pharmaceuticals company Meda AB (OMX Stockholm: MEDA A) said on Friday (13 September) that it has completed its previously announced acquisition of the European operations...

  Articles 2008-09-12

• Valeant Pharmaceuticals Completes Sale of Certain European Operations to Meda AB

  ALISO VIEJO, Calif. -- Valeant Pharmaceuticals International (NYSE:VRX) announced today that it has completed its sale of certain business operations located in Western Europe, Eastern Europe, and certain export markets to Meda AB, pursuant to the Acquisition Agreement entered into by Meda and Valeant on August 4, 2008. Valeant received...

  Articles 2008-09-12